NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company
focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a
conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, November 7, 2018, to provide a
corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2018.
To access the live conference call via phone, dial 1-(844) 835-6563. The International dial-in number is 1-(970) 315-3916. The
conference ID number for the live call is 4966996.
The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's
website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to
register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and
diseases of the elderly, including Parkinson’s and Alzheimer’s disease. The Company is developing its lead drug candidate,
lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients
with dementia, including Alzheimer’s disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a
first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation
associated with dementia, including Alzheimer’s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and
other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the
Company’s PDE1 portfolio, ITI-214 is in development for the treatment of symptoms associated with Parkinson's
disease. Ultimately, treatments are needed that protect dopamine containing neurons from damage, providing novel approaches
for slowing or halting disease progression. The impact of ITI-214 may be examined in future, longer term studies.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Lisa Burns
agray@burnsmc.com
212-213-0006
MEDIA INQUIRIES:
Patrick Ryan, Esq.
Corporate Media Relations, W2Owcg
pryan@wcgworld.com
